Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS).

Full DD Report for CRVS

You must become a subscriber to view this report.


Recent News from (NASDAQ: CRVS)

Corvus Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
BURLINGAME, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the first quarter ende...
Source: GlobeNewswire
Date: May, 03 2018 16:10
3 Things In Biotech, April 30: Another ADC, Another Breakthrough, Another Immunotherapy
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a...
Source: SeekingAlpha
Date: May, 01 2018 08:00
Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer
BURLINGAME, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it is enrolling patients in a multice...
Source: GlobeNewswire
Date: April, 26 2018 08:30
Surface Oncology Proposes IPO Terms
Quick Take Surface Oncology ( SURF ) aims to raise $84 million in a U.S. IPO of its common stock, according to an amended S-1/A registration statement . The company has a pipeline of cancer treatment drug candidates focused on affecting the tumor microenvironment. SURF’s lead c...
Source: SeekingAlpha
Date: April, 09 2018 12:40
Surface Oncology Files For $75 Million IPO
Quick Take Surface Oncology ( SURF ) intends to sell shares of its common stock for gross proceeds of $75 million from a U.S. IPO, according to an S-1 registration statement . The firm is a clinical-stage immuno-oncology company developing next-generation antibody therapies that targe...
Source: SeekingAlpha
Date: April, 05 2018 08:36
Corvus Pharmaceuticals: A New Immunotherapy Player
The immune checkpoints are signaling molecules that act to shut down or block an immune response. In a healthy person, this mechanism is a "safety" feature allowing cessation of the immune response once it has performed its task. Cytotoxic T Lymphocyte Antigen 4 (CTLA‐4) and programd D...
Source: SeekingAlpha
Date: April, 04 2018 08:37
Blog Exposure - Checkpoint Therapeutics to Present Preclinical Data on its BET Inhibitor CK-103 at AACR Meeting
Stock Monitor: Corvus Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 19, 2018 / Active-Investors.com has just released a free research report on Checkpoint Therapeutics, Inc. (NASDAQ: CKPT ). If you want access to this report all you need to do is sign up now by click...
Source: ACCESSWIRE IA
Date: March, 19 2018 07:40
Daily Insider Ratings Round Up 3/14/18: CRVS, ECL, NMFC, BDGE, AAT, TEI, WTTR
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: March, 15 2018 20:07
Daily Insider Ratings Round Up 3/13/18: VRX, CRVS, NIHD, ETM, LGCY, ECL, PK
InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: March, 15 2018 12:20
Daily Insider Ratings Round Up 3/12/18: NMFC, FLDM, DFRG, SCM, TSI, GOGO, CRVS, EGN
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: March, 14 2018 09:09

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1810.1210.8910.9510.0995,337
2018-05-179.8210.0710.1689.539185,535
2018-05-169.519.8110.169.420376,559
2018-05-159.799.4910.1159.0547,459
2018-05-149.919.8310.599.7955,140

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2110,35619,00454.4938Short
2018-05-183,67733,17911.0823Cover
2018-05-1722,28833,14167.2520Short
2018-05-1615,59618,07886.2706Short
2018-05-157,59816,52745.9733Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CRVS.


About Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS)

Logo for Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $287,556,960 - 05/11/2018
  • Issue and Outstanding: 29,193,600 - 05/03/2018

 


Recent Filings from (NASDAQ: CRVS)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: March, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 19 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 14 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 13 2018

 

 


Daily Technical Chart for (NASDAQ: CRVS)

Daily Technical Chart for (NASDAQ: CRVS)


Stay tuned for daily updates and more on (NASDAQ: CRVS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CRVS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CRVS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of CRVS and does not buy, sell, or trade any shares of CRVS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/